Aldeyra Therapeutics, Inc. (ALDX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001341235 Massachusetts 0001341235 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report
How this was made
The 30-second read
Why it matters
The primary new information is the appointment of a new independent audit committee chair and the associated equity/fee compensation structure; the rest of the filing reports routine shareholder vote tallies.
Market read
Governance update with disclosed compensation and shareholder vote results; no new clinical, financial, or regulatory catalyst is provided.
What to watch
The 8-K also includes stockholder vote results (director election, BDO ratification, advisory say-on-pay), but no vote outcome suggests a major dispute or turnaround.
Background
This is an SEC Form 8-K (Item 5.02) describing director/officer changes and director compensation following Aldeyra’s 2026 annual meeting.
Ticker impact
Aldeyra appointed Darlene Deptula-Hicks as a Class III director and audit committee chair, including new equity/fee compensation details in an 8-K.
Limited near-term price impact; any reaction is likely muted unless investors view the appointment as materially strengthening audit oversight.
The filing is a routine governance update (director appointment and compensation terms) without clinical, financial, or regulatory developments.
Market effects
Minimal; audit-committee leadership changes are company-specific and not a sector-wide signal here.
None indicated.
None indicated.
Counterpoint
The appointment could be interpreted as improving audit/controls readiness, which may matter if the market is already concerned about governance or reporting quality—though no such concern is stated in the filing.
Key entities
- Director/Audit Committee ChairDarlene Deptula-Hicks
Appointed Class III director and audit committee chair; granted a non-statutory stock option and annual director/audit chair fees.
- Independent Registered Public Accounting FirmBDO USA, P.C.
Stockholders ratified BDO as independent auditor for fiscal year ending Dec. 31, 2026.
- Director (Class III)Todd C. Brady, M.D., Ph.D.
Elected director in Proposal 1; vote totals disclosed in Item 5.07.
